Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

Gillian Thomas*, Shamshad Ali, Frank J.P. Hoebers, Kathleen M. Darcy, William H. Rodgers, Malti Patel, Ovardia Abulafia, Joseph A. Lucci, Adrian C. Begg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

147 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences